Clinical Trial Manager
Summit Therapeutics
10/30/2025
About the Role
About Summit:
Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational
bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects
associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its
intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF.
Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), with three active Phase
Responsibilities
- Perform core duties as described.
Requirements
- Relevant experience or willingness to learn.
Benefits
- Benefits per job description.
Compensation
To be discussed.
Location & Schedule
Per job description.
How to Apply
Use the “Apply” button.